Mupirocin (Supiroban, Mupirocin Glenmark)
Mupirocin
Glenmark Pharmaceuticals South Africa (Pty) Ltd
Registration
- Applicant
- Glenmark Pharmaceuticals South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Supiroban EACH 1,0 g OINTMENT CONTAINS MUPIROCIN 20,0 mg | Not listed | 43068043/20.1.6/0680 | Registered | Not determined | None |
| Mupirocin ointment glenmark Each 1,0g of ointment contains MUPIROCIN 20,0 mg | Ointment | 47072847/20.1.6/0728 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Mupirocin
- except when intended for topical application to the epidermis, nares and external ear.
Consolidated Schedules 06 July 2026, line 7193
S2: Mupirocin
- when intended for application to the skin, nares and external ear.
Consolidated Schedules 06 July 2026, line 2359
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.